[Effect of tolvaptan on ascites due to malignancy].
Ascites accompanying a malignancy is often refractory to conventional treatment with saline diuretics, making it difficult to control. We administered a new diuretic, Tolvaptan, to 10 individuals with malignancy and heart failure accompanied by ascites, which was refractory to saline diuretics, and assessed its efficacy and adverse events. We observed a significant reduction in abdominal distension following 2 weeks of Tolvaptan administration. However, we also observed significant increases in serum potassium, urea nitrogen, and creatinine levels, but no serious adverse events. This suggests that Tolvaptan may also be effective as treatment for ascites.
Dept. of Gastroenterology and Surgery, Narashino Daiichi Hospital.
Noboru
N
Mitsuhashi
Shigeyoshi
S
Nemoto
Yutaka
Y
Satoh
Yu
Y
Aoki
Ryotaro
R
Teranaka
Kousuke
K
Sasaki
Reiri
R
Shimazaki
Atsuhiko
A
Ueda
Hitoe
H
Nishino
Takahiro
T
Akiyama
Isamu
I
Hosokawa
Takuya
T
Yoichi
Jun
J
Kawamoto
Satoshi
S
Kuboki
Hideyuki
H
Yoshitomi
Atsushi
A
Kato
Yoshiaki
Y
Shimizu
Masayuki
M
Ohtsuka
Hiroaki
H
Shimizu
Masaru
M
Miyazaki
D000368:Aged; D000369:Aged, 80 and over; D065092:Antidiuretic Hormone Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D000077602:Tolvaptan
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan